Background
Weight gain might occur in people with HIV (PWH) switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF)-based antiretroviral therapy (ART), but data regarding body composition are missing. The objective of the study was to explore body composition (BC) changes in PWH switching from or maintaining TDF-based ART.
Methods
This was anobservational longitudinal study including ART-experienced PWH attending the Modena HIV Metabolic Clinic (Italy) from 2004 to Feb 2024 with at least 3 assessments for BC, measured by dual energy X-ray absorptiometry (DEXA). BC comprised total lean and fat mass, including trunk fat. Baseline (time 0, T0) was defined as the first available DEXA in which TDF-based ART was recorded. In the switching groups, time 1 (T1) was the date of switching to TAF (group 2) or abacavir (ABC) and/or lamivudine (3TC)-based ART (group 3), while in PWH who maintained TDF (group 1) was the closest date to other two groups. Groups were matched for median time duration between T0 and T1. Time 2 (T2) was defined as 2 years after the switch in all groups. The effect of switching from or maintaining TDF on BC changes was explored in the linear mixed model (LMM) adjusted for age and sex.
Results
A total of 1235 PWH were included (29.5% women). At T0, median age was 45 yrs, median BMI was 23.4 kg/m2, median CD4 cell count 590 c/microL. At T1, groups 2 and 3 were older (Group 1, 2, 3: 48, 53, 50 yrs) and had higher: BMI (Group 1, 2, 3: 23.6, 24.5, 23.4 kg/m2), total fat (Group 1, 2, 3: 15, 21, 16 kg) and trunk fat (Group 1, 2, 3: 8, 8.6, 11 kg) compared to Group 1 (all p<0.001). No differences were observed in total lean mass among the groups at T1. After a follow-up of 2 years, differences were observed in BMI (Group 1, 2, 3: 23.6, 24.5, 23.5 kg/m2), total (Group 1, 2, 3: 16, 21, 17 kg) and trunk (Group 1, 2, 3: 8.4, 10.8, 9.1 kg) fat mass (all p<0.001). In LMM, at T2, trends for BMI and lean mass increase were significantly higher in PWH switching to TAF or ABC and/or 3TC when compared to PWH maintaining TDF (Table 1). Conversely, trends for total fat and trunk increase were higher in PWH maintaining TDF when compared to switching to TAF (Table 1). Trends over time for BC changes among the groups is shown in Table 1.
Conclusions
After 2 years of follow-up, maintaining TDF was associated with decrease in BMI and total lean mass, suggesting that weight loss observed with TDF regimens might be related to unhealthy lean loss.
Table or Figure
![]()